Floatz logo

Autologous Cd30.Car-T

Hodgkin Disease Refractory

Tessa TherapeuticsCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

149 Active assets in the Hodgkin Disease Refractory cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 3BBB
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BBB
Everolimus
OHSU Knight Cancer Institute
Phase 2BBB
CARMUSTINE
VIVUS LLC
Phase 2BBB
Cytosin-Arabinosid
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BBB

View all 50 →

Same molecule, other indications

Autologous Cd30.Car-T is also rated in:

classic Hodgkin lymphomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →